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society and the MoH. Indirect costs were in all cases higher than
direct costs.
PIH21
ADJUSTMENT FOR PUBLICATION BIAS CHANGES THE
APPARENT EFFICACY OF HORMONE TREATMENT-
UNADJUSTED DATA MIGHT DISTORT THE RISK–BENEFIT
TRADE OFF
Badamgarav E1, Borenstein J2, Song PJ1, Dubois RW1
1Cerner Health Insights, Beverly Hills, CA, USA; 2Cedars-Sinai Health
System, Los Angeles, CA, USA
OBJECTIVES: To determine the impact of publication bias on
the magnitude of the treatment effect in clinical studies evaluat-
ing hormone therapy (HT) on the frequency of hot ﬂashes among
menopausal women. METHODS: We searched computerized
databases for English language articles from 1966 to April, 2004.
Two reviewers evaluated 5840 published titles, identiﬁed
placebo-controlled observations that met explicit inclusion cri-
teria, and extracted data pertaining to study characteristics,
interventions used, and outcomes measured. Studies evaluating
the effects of HT in cancer patients were excluded. The impact
of HT on the frequency of hot ﬂashes was calculated using a
random-effects model. The effects of publication bias were
assessed using the trim and ﬁll method. RESULTS: Based on our
criteria, a total of 29 studies were included in the meta-analysis.
A funnel plot examining the presence of publication bias was
asymmetric, suggesting that small non-signiﬁcant studies were
missing. The trim and ﬁll method suggested that four studies
were missing. The standardized mean difference between 
unadjusted and adjusted point estimates was 0.8 (CI 0.3–1.2).
CONCLUSIONS: When evaluating the efﬁcacy and safety of
therapeutic interventions, the validity of ﬁndings from a meta-
analysis is questionable if publication bias is present. Given that
restricting a meta-analysis to published literature can distort the
effects under investigation by as much as 30%, researchers
should try to detect and correct for publication bias when syn-
thesizing the evidence. Our meta-analysis conﬁrmed that HT is
effective in relieving menopause-related hot ﬂashes but less than
originally suggested. For therapies with signiﬁcant risk-beneﬁt
tradeoffs, the clinical decision could vary upon a complete and
unbiased assessment.
PIH22
NEW INSIGHTS INTO THE PLACEBO EFFECTS: A CASE
STUDY OF THE EFFECTIVENESS OF HORMONE THERAPY ON
THE FREQUENCY OF HOT FLASHES
Song PJ1, Badamgarav E1, Dubois RW1, Borenstein J2
1Cerner Health Insights, Beverly Hills, CA, USA; 2Cedars-Sinai Health
System, Los Angeles, CA, USA
OBJECTIVES: To determine the magnitude of the placebo effect
in studies examining the impact of hormone therapy (HT) on 
the frequency of hot ﬂashes among menopausal women. We 
also examined the inﬂuence of data type on point estimates.
METHODS: We searched computerized databases for English
language articles from 1966 to April, 2004. Two reviewers eval-
uated 5840 published titles, identiﬁed placebo-controlled obser-
vations that met explicit inclusion criteria, and extracted data
pertaining to study characteristics, interventions used, and out-
comes measured. Studies evaluating the effects of HT in cancer
patients were excluded. The magnitude of the placebo effect on
frequency of hot ﬂashes was calculated using a random-effects
model. The effects of outcome type (binary and continuous) were
assessed separately. RESULTS: Based on our criteria, a total of
25 studies were included in the meta-analysis. When the effects
of data type were assessed, studies with continuous outcomes (N
= 18) reported a larger placebo effect than studies using binary
outcomes (N = 7). The difference in standardized mean differ-
ence (SMD) = 2.52 (CI: 2.17–2.8). A larger placebo effect was
observed in weekly hot ﬂashes. The difference between weekly
and daily SMD = 0.5 (CI: 0.15–0.85). CONCLUSIONS: Place-
bos are used to control for natural remission and provide a stan-
dard for comparison to active treatment. However, it is difﬁcult
to distinguish a true placebo effect from reporting bias when
studying hot ﬂashes; patients tend to please investigators by
reporting positive changes when no improvement took place.
Overall, we found a greater placebo effect in studies with con-
tinuous outcomes possibly due to the systematic differences in
the self-recording of symptoms or the natural decline of symp-
toms. These ﬁndings may apply to other patient reported out-
comes in other conditions.
PIH23
HEALTH PREFERENCES AND WILLINGNESS TO PAY TO
REDUCE EXPOSURE TO POST-MENOPAUSAL RISK FACTORS
Szeinbach SL1, Harpe SE2, Fouad M3, Ohsfeldt RL4
1Ohio State University, Columbus, OH, USA; 2Virginia
Commonwealth University, Richmond,VA, USA; 3University of
Alabama at Birmingham, Birmingham, AL, USA; 4The University of
Iowa College of Public Health, Iowa City VAMC, IA, USA
OBJECTIVES: This study uses conjoint analysis to examine
women’s health preferences toward three post-menopausal risk
factors: osteoporosis, heart disease, and breast cancer. Willing-
ness to pay (WTP) to reduce the risk of exposure was also exam-
ined. METHODS: A questionnaire containing three parts:
conjoint analysis to assess health preferences toward the easiest
(hardest) condition to live with (levels: 25%, 50%, 75%), WTP
to reduce risk factor exposure 0%, 50%, 25%, respectively, and
demographic characteristics was administered to a random
sample of women currently participating in a large observational
study at the University of Alabama Birmingham, School of 
Medicine. Of the 99 responses obtained, 83 were suitable for
conjoint analysis. Visual analog scales established validity and
quality of life measures assessed current health status. RESULTS:
Overall utilities for the best possible preferences were 1.573, 
-0.696, -0.877 for osteoporosis, heart disease, and breast
cancer, respectively, with Log likelihood = -1077.21, X2 = 671.4, 
P < 0.001, Pseudo R = 0.24 for the binary logit model. Similar
patterns were observed for the worst possible preferences.
Average WTP values to reduce exposure to the three risk factors
levels that were the easiest to live with ranged from $224.50 to
$3500. Alternatively, WTP values to reduce exposure for risk
factor levels that were the hardest to live with ranged from
$425.00 to $6500. Patient preferences were consistent with the
assumptions of decision theory and income levels. CONCLU-
SIONS: Findings from this study reveal the usefulness of con-
joint analysis to assess health preferences with respect to disease
severity, risk, and the possibility of future encounters.
INFECTION
PIN1
OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN 
NON-ELDERLY ADULTS: TREATMENT AND OUTCOMES
Singer ME1,Asche CV2, Rose J1
1Case School of Medicine, Cleveland, OH, USA; 2University of Utah,
Salt Lake City, UT, USA
OBJECTIVE: To examine antibiotic prescribing and outcomes
in outpatient treatment of community-acquired pneumonia in
non-elderly adults. METHODS: We analyzed claims from eight
managed care organizations. Index claims were outpatient or
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emergency department visits in 1999–2001 by individuals aged
25–64 with primary diagnosis of pneumonia, antibiotic pre-
scription within three-days, chest x-ray on index date, continu-
ous enrollment for 12-months prior, 30-days after index visit.
Exclusion criteria: antibiotic prescription, pneumonia diagnosis,
or hospitalization in prior 30-days; initial therapy with multiple
antibiotics; in prior 12-months residence in a long-term 
care facility or diagnosis of cancer of bronchus or lung, sec-
ondary malignancy, HIV/AIDS, cystic ﬁbrosis, immunity disor-
ders. We considered the following comorbid illnesses: chronic
liver, renal or lung disease; cerebrovascular disease; cardiac
disease; diabetes mellitus; malignancy. RESULTS: A total of
5748 cases met criteria, 13.9% initially seen in the emergency
department. Of these, 16.8% had one comorbidity, 3.5% had
multiple comorbidities. Macrolides were the most common
initial therapy (66.5%), followed by quinolones (17.9%).
Quinolone use more than doubled from 1999 to 2001, from
11.8% to 24.3% in patients without comorbidity, from 12.1%
to 33.8% in patients with comorbidities. Overall, 13.1%
received a change in therapy without subsequent hospitalization,
another 3.0% were hospitalized. Females were more likely to
change therapy than males (15.9% vs. 10.5%, p < 0.0001) but
not more likely to be hospitalized (3.0% for both). Failure rates
were strongly associated with number of comorbidities (p =
0.0004), particularly in rates of subsequent hospitalization:
2.4% for no comorbidities, 4.9% for one comorbidity and 7.5%
for multiple comorbidities. Hospitalization without secondary
outpatient therapy was common: 13.5% for patients without
comorbidity, 24.9% for one comorbidity, 28.6% for multiple
comorbidities. CONCLUSION: While macrolides were the most
common therapy, quinolone usage was substantial and rising
rapidly regardless of comorbidity. Hospitalization for patients 
failing therapy was fairly common even in patients without
comorbidity.
PIN2
EFFECT OF INAPPROPRIATE ANTIBIOTIC THERAPY ON
CLINICAL OUTCOMES OF PATIENTS WITH PSEUDOMONAS
AERUGINOSA BACTEREMIA
Rao B,Tam V, Garey KW
University of Houston, College of Pharmacy, Houston,TX, USA
OBJECTIVE: Infections due to P. aeruginosa are associated with
increased likelihood of death and morbidity. Empiric therapy is
often difﬁcult due to increased resistance noted with this organ-
ism. The purpose of this study was to determine the impact of
inappropriate initial empiric therapy on health outcomes of
patients with P. aeruginosa bacteremia. METHODS: Retrospec-
tive cohort study of hospitalized patients with their ﬁrst episode
of P. aeruginosa bacteremia. Patients were stratiﬁed based on
appropriateness of antipseudomonal therapy. Inappropriate
initial empiric therapy was deﬁned as receipt of antibiotic
therapy to which the isolate displayed in vitro resistance. Data
collected included discharge mortality, new ICU admit, new
requirement for ventilator therapy or hemodialysis, and length
of hospital stay. RESULTS: A total of 87 patients (71%
males/29% females) aged 58 ± 17 years (mean ± SD) were iden-
tiﬁed between January, 2002 to April, 2004. Overall mortality
was 44%. Forty-nine percent of patients’ received inappropriate
antibiotic therapy. ApacheII score were signiﬁcantly higher in
patients that died (p = 0.003). Mortality rates were signiﬁcantly
higher in patients treated with inappropriate empiric therapy
(63%) compared to patients treated appropriately (39%, OR =
2.97, p = 0.024). New requirements for ICU admission,
hemodialysis, or ventilator did not differ between the two
groups. CONCLUSIONS: Inappropriate initial empiric therapy
in patients with P. aeruginosa bacteremia signiﬁcantly increased
mortality rates.
PIN3
DURATION OF ANTIBIOTIC TREATMENT IN HOSPITALIZED
PATIENTS WITH COMPLICATED SKIN AND SKIN 
STRUCTURE INFECTIONS (CSSSI): FINDINGS FROM A
CLINICAL STUDY COMPARING TIGECYCLINE AND
VANCOMYCIN/AZTREONAM
Yu H1, Mallick R1,Weber DJ2
1Wyeth Research, Collegeville, PA, USA; 2University of North
Carolina, Chapel Hill, NC, USA
OBJECTIVES: We sought to evaluate which risk factors may be
implicated in prolonged duration of antibiotic treatment in hos-
pitalized patients with complicated skin and structure infections
(cSSSI). METHODS: We pooled data from two double-blind,
randomized, multinational, clinical trials among patients with
cSSSI. Patients were randomly assigned to receive either tigecy-
cline (initial 100mg dose, followed by 50mg twice daily) or van-
comycin with aztreonam (1g vancomycin plus 2g aztreonam,
twice daily) via IV administration. Treatment termination was
based on physician assessment of resolution of signs and symp-
toms of infection, with formal test of cure (TOC) at least 12-
days later. We used a Cox proportional hazard (CPH) model 
to identify potential clinical risk factors for longer time-to-
treatment termination. RESULTS: Among 1041 patients in the
modiﬁed intent-to-treat (m-ITT) population with complete hos-
pitalization data, deep/extensive cellulitis (59%) was the most
common cSSSI diagnosis, spontaneous infection (51%) was the
typical etiology, and diabetes (22%) was the most common
comorbidity. No signiﬁcant differences were observed in baseline
characteristics. Median treatment duration was eight-days for
each treatment group. The estimated CPH model identiﬁed dia-
betes (p < 0.0001), female sex (p = 0.017), infected ulcer (p =
0.001), and use of concomitant antibiotics (p = 0.002) as inde-
pendent risk factors for signiﬁcantly longer treatment duration.
Adjusting for these risk factors, tigecycline was associated with
a trend toward shorter treatment duration overall (p = 0.072)
and within the diabetes, infected ulcer, and female strata. There
was no difference across the treatment groups in the rate of cure
at the TOC visit (p = 0.197). CONCLUSIONS: Diabetes, female
sex, infected ulcers, and use of concomitant antibiotics emerged
as signiﬁcant risk factors for prolonged treatment duration in
cSSSI. Tigecycline, the ﬁrst in a new antibiotic class, the glycyl-
cyclines, was associated with a trend toward shorter treatment
duration, once the risk factors were adjusted for.
PIN4
IMPACT OF EMPIRIC ANTIFUNGAL THERAPY ON 
MORTALITY IN HOSPITALIZED PATIENTS WITH
BLOODSTREAM CANDIDEMIA
Rege M1, Garey KW1, Gentry L2
1University of Houston, College of Pharmacy, Houston,TX, USA;
2St. Luke’s Episcopal Hospital, Houston,TX, USA
OBJECTIVE: The objective of this study was to determine the
impact of empiric antifungal therapy on mortality in hospital-
ized, non-neutropenic patients with bloodstream candidemia.
METHODS: Retrospective cohort study to evaluate the effect of
empiric therapy on mortality in patients with bloodstream can-
didemia. Medical and hospitalization history were collected from
the medical charts of patients hospitalized from 2002 to 2004
with their ﬁrst documented episode of candidemia. Patients were
grouped by APACHEII scores and choice of empiric antifungal
therapy (narrow spectrum: ﬂuconazole or itraconazole; broad
spectrum: amphotericin, caspofungin, or voriconazole). Impact
